Disease Domain | Count |
---|---|
Neoplasms | 3 |
Nervous System Diseases | 2 |
Hemic and Lymphatic Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Synthetic peptide | 1 |
CRISPR/Cas9 | 1 |
AAV based gene therapy | 1 |
Target |
Mechanism CD4 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GIPR agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2025 |
Sponsor / Collaborator ![]() [+10] |
Start Date10 Oct 2024 |
Sponsor / Collaborator |
Start Date01 Jun 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
LM49 ( CD4 ) | Diabetic Nephropathies More | Phase 1 |
DA5-CH ( GIPR x GLP-1R ) | Alzheimer Disease More | Preclinical |
CN118530124 Patent Mining | Myocardial Ischemia More | Discovery |
CN114957289 ( IGKV5-2 x LCN2 x TIM1 )Patent Mining | Neoplasms More | Discovery |
CN119875630 ( CDS1 )Patent Mining | Hemolysis More | Discovery |